Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate

International Journal of Radiation Biology

Volumn 72, Issue 2, 1997, Pages 211-218

  Miller, A C ^a   Whittaker, T ^a   Thibault, A ^b   Samid, D ^b  

^a ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; PHENYLACETIC ACID;

ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE G1 PHASE; COLON CANCER; DOSE TIME EFFECT RELATION; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIFFERENTIATION; CELL SURVIVAL; HUMANS; PHENYLACETATES; PHENYLBUTYRATES; RADIATION TOLERANCE; TUMOR CELLS, CULTURED;

EID: 0030802401     PISSN: 09553002     EISSN: None     Source Type: Journal    
DOI: 10.1080/095530097143437     Document Type: Article

References (38)

1. ANGIOLI, R., SEVIN, B., PERRAS, J. P., UNTCH, M., KOECHLI, O. R., NGUYEN, H. N., STEREN, A., SCHWADE, J. G., VILLANI, C. and AVERETTE, H. E., 1993, In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell lines. Cancer, 71, 3717-3725.
2. ARUNDEL, C. M., GLICKSMAN, A. S. and LEITH, J. T., 1985, Enhancement of radiation injury in human colon tumour cells by the maturational agent sodium butyrate (NaB). Radiation Research, 104, 443-448.
3. ARUNDEL, C. M., KENNEY, S. M., LEITH, J. T. and GLICKSMAN, A. S., 1986, Contrasting effects of the differentiating agent sodium butyrate on recovery processes after X-irradiation in heterogenous human colon tumour cells. International Journal of Radiation Oncology, Biology, Physics, 12, 959-968.
4. BIAGLOW, J. E., VARNES, M. E., CLARK, E. P. and EPP, E. R., 1983, The role of thiols in cellular response to radiation and drugs. Radiation Research, 95, 437-455.
5. BILL, C. A., VINES, C. M., GARRETT, K. C., YAMADA, K. and TOFILON, P. J., 1990, Enhancement of the radiosensitivity of two human tumour cell lines by hexamethylene bisacetamide. British Journal of Cancer, 61, 563-567.
6. CARDUCCI, M. A., NELSON, J. B., CHAN-TACK, K. M., AYYAGARI, S. R., SWEATT, W. H., CAMPBELL, P. A., NELSON, W. G. and SIOMONS, J. W., 1996, Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clinical Cancer Research, 2, 379-387.
7. 2-M phase of the cell cycle. Cancer Research, 47, 4338-4341.
8. CHAVAUDRA, N., HALIMI, M., PARAMENTIER, C., GAILLARD, N., GRINFELD, S. and MALAISE, E. P., 1989, The initial slope of human tumour cell survival curves: its modification by the oxic cell sensitizer B-arabinofuranosyladenine. International Journal of Radiation Oncology, Biology, Physics, 16, 1267-1271.
9. DEXTER, D. L., LEE, E. S., BLIVEN, S. F., GLICKSMAN, A. S. and LEITH, J. T., 1984, Enhancement by N-methylformamide of the effect of ionizing radiation on a human colon tumour xenografted in nude mice. Cancer Research, 44, 4942-4946.
10. DOVER, G. J., BRUSILOW, S. and SAMID, D., 1992, Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. New England Journal of Medicine, 327, 569-570.
11. JAMES, M. O., SMITH, R. L., WILLIAMS F. R. S. and REIDENBERG, M., 1972, The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species. Proceedings of the Royal Society of London B, 182, 25-35.
12. KALINICH, J. F., CATRAVAS, G. N. and SNYDER, S. L., 1991, Radioprotective properties of DNA methylation-disrupting agents. International Journal of Radiation Biology, 59, 1217-1226.
13. KLIMBERG, V. S., SALLOUM, R. M., KASPER, M., PLUMLEY, D. A., DOLSON, D. J., HAUTAMAKI, R. D., MENDENHALL, W. R., BOVA, F. C., BLAND, K. I. and COPELAND, E. M., 1990, Oral glutamine accelerates healing of the small intestine and improves outcomes after whole abdominal radiation. Archives of Surgery, 125, 1040-1045.
14. KUMAR, K. S., VAISHNAV, Y. N. and WEISS, J. F., 1988, Radioprotection by antioxidant enzymes and enzyme mimetics. Pharmacology and Therapeutics, 39, 301-309.
15. KUO, M. L., KUNUGI, K. A., LINDSTROM, M. J. and KINSELLA, T. J., 1995, The interaction of hydroxyurea and iododeoxyuridine on the radiosensitivity of human bladder cancer cells. Cancer Research 55, 2800-2805.
16. LEITH, J. T., GASKINS, L. A., DEXTER, D. L., CALABRESI, P. and GLICKSMAN, A. S., 1982, Alteration of the survival response of two human colon carcinoma subpopulations to X-irradiation by N, N-dimethylformamide. Cancer Research, 42, 30-34.
17. LIU, L., SHACK, S., STETLER-STEVENSON, W. G., HUDGINS, W. R. and SAMID, D., 1994, Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. Journal of Investigative Dermatology, 103, 335-340.
18. MILLER, A. C. and BLAKELY, W. F., 1992, Inhibition of glutathione reductase activity by a carbamoylating nitrosourea: effect on cellular radiosensitivity. Free Radical Biology and Medicine, 12, 53-62.
19. MILLER, A. C., KARIKO, K., MYERS, G. E., CLARK, E. P. and SAMID, D., 1993, Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. International Journal of Cancer, 53, 302-307.
20. MILLER, A. C. and SAMID, D., 1995, Tumor resistance to oxidative stress: association with ras oncogene expression and reversal by lovastatin, an inhibitor of p21ras isoprenylation. International Journal of Cancer, 60, 249-254.
21. MOSLEN, M. T., 1992, Protection against free-radical-mediated tissue injury. In Free Radical Mechanism of Tissue Injury, edited by M. T. Molson and C. V. Smith (Boca Raton: CRC Press), pp. 203-215.
22. O'CONNELL, M. J., MARTENSON, J. A., WEAND, H. S., KROOK, J. E., MACDONALD, J. S., HALLER, D. G., MAYER, R. J., GUNDERSON, L. L. and RICH, T. A., 1994, Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. New England Journal of Medicine, 331, 502-507.
23. PINEAU, T., HUDGINS, W. R., LIU, L., CHEN, L., SHER, T., GONZALEZ, F. J. and SAMID, D., 1996, Activation of a human pcroxisome proliferator-activated receptor by the antitumour agent phenylacetate and its analogs. Biochemical Pharmacology, 52, 659-667.
24. PRADOS, M. D., SPENCE, A., SCHOLD, C., ROBBINS, I., MEHTA, M., BERGER, M., KUHN, J., RRECTOR, D., CHANG, S. and GILBERT, M., 1996, A phase II trial of phenylacetic acid for recurrent malignant glioma. Proceedings of the American Society of Clinical Oncology, 15, 51-56.
25. PRASANNA, P., SHACK, S., WILSON, V. L. and SAMID, D., 1995, Phenylacetate in chemoprevention: in vitro and in vivo suppression of 5-aza-2′-deoxycytidine-induced carcinogenesis. Clinical Cancer Research, 1, 865-871.
26. PU, A. T., ROBERTSON, J. M. and LAWRENCE, T. S., 1995, Current status of radiation sensitization by fluoropyrimidines. Oncology, 9, 707-714.
27. SAMID, D., SHACK, S. and MYERS, C. E., 1993, Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. Journal of Clinical Investigation, 91, 2288-2295.
28. SAMID, D., SHACK, S. and SHERMAN, L., 1992a, Phenylacetate: a novel nontoxic indurer of tumour cell differentiation. Cancer Research, 52, 1988-1992.
29. SAMID, D., RAM, Z., HUDGINS, W. R., SHACK, S., LIU, L., WALBRIDGE, S., OLDFELD, E. H. and MYERS, C. E., 1994, Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain ketonuria. Cancer Research, 54, 891-895.
30. SAMID, D., YEH, A. and PRASANA, P., 1992b, Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 80, 1576-1581.
31. SHACK, S., CHEN, L., MILLER, A. C., DANESI, R. and SAMID, D., 1995, Increased susceptibility of ras transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. International Journal of Cancer, 63, 124-129.
32. SHACK, S., MILLER A. C., LIU, L., PRASANNA, P., THIBAULT, A. and SAMID, D., 1996, Vulnerability of multidrug resistant tumour cells to aromatic fatty acids phenylacetate and phenylbutyrate. Clinical Cancer Research, 2, 865-872.
33. SINCLAIR, W. K. and MORTON, R, A., 1966, X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radialion Research, 29, 450-474.
34. SKOV, K. A. and MACPHAIL, S., 1994, Low concentrations of nitroimidazoles: effective radiosensitizers at low doses. International Journal of Radiation Oncology, Biology, Physics, 29, 87-93.
35. TANNOCK, I. F. SUIT, H. D, and MARSHAL, N., 1972, Vitamin A and the radiation response of experimental tumours. Journal of the National Cancer Institute, 3, 731-741.
36. THIBAULT, A., COOPER, M. R., FIGG, W. D., VENZON, D. J., SARTOR, A. O., TOMPKINS, A. C., WEINBERGER, M. S., HEADLEE, D. J., MCCALL, N. A., SAMID, D. and MYERS, C. K., 1994, A phase I and pharmacokinetics study of intravenous phenylacetate in patients with cancer. Cancer Research, 54, 1690-1694.
37. THIBAULT, A., FIGG, W. D. and SAMID, D., 1996, A phase I study of the differentiating agent phenylbutyrate in patients with cancer. Program/Proceedings of The American Society of Clinical Oncology, 15, 484.
38. THIBAULT, A., SAMID, D., COOPER, M. R., FIGG, W. D., TOMPKINS, A. C., PATRONAS, N., HEADLEE, D. J., KOHLEY, D. R., VENZON, D. J. and MYERS, C. E., 1995, Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer, 75, 2932-2938.